^
Association details:
| Biomarker: | BCL2 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Systems Biology Approach to Identify Mechanisms of Therapy Resistance in Multiple Myeloma
Published date:
11/01/2018
Excerpt:
The analysis conducted in MM samples tested with ABT-199 agreed with previous clinical studies in MM, pointing to over-expression of Bcl-xl and Mcl1, as well as under-expression of Bim, Bcl-2, and NOXA in resistant samples.
